NDLI: A distinct p53 target gene set predicts for response to the selective p53

Content Provider	PubMed Central
Author	Sébastien, Jeay Swann, Gaulis Ferretti, Stéphane Bitter, Hans Ito, Moriko Valat, Thérèse Murakami, Masato Ruetz, Stephan Guthy, Daniel A. Rynn, Caroline Jensen, Michael R. Wiesmann, Marion Kallen, Joerg Furet, Pascal François, Gessier Holzer, Philipp Masuya, Keiichi Jens, Würthner Halilovic, Ensar Hofmann, Francesco Sellers, William R. Porta, Diana Graus
Editor	Espinosa, Joaquin M.
Copyright Year	2015
Abstract	Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53–HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression signature consisting of 13 up-regulated genes that predicts for sensitivity to NVP-CGM097 in both cell lines and in patient-derived tumor xenograft models. Interestingly, these 13 genes are known p53 downstream target genes, suggesting that the identified gene signature reflects the presence of at least a partially activated p53 pathway in NVP-CGM097-sensitive tumors. Together, our findings provide evidence for the use of this newly identified predictive gene signature to refine the selection of patients with wild-type p53 tumors and increase the likelihood of response to treatment with p53–HDM2 inhibitors, such as NVP-CGM097.
Related Links	http://dx.doi.org/10.7554/eLife.06498
Starting Page	6498
File Format	PDF
ISSN	2050084X
e-ISSN	2050084X
Journal	eLife
Volume Number	4
Language	English
Publisher	eLife Sciences Publications, Ltd
Publisher Date	2015-05-12
Access Restriction	Open
Rights Holder	eLife Sciences Publications, Ltd
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Neuroscience Immunology and Microbiology Medicine Biochemistry, Genetics and Molecular Biology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097

NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance

A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response

Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit

MDMX regulation of p53 response to ribosomal stress

Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein

Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Similar Documents

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097

NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance

A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response

Regulation of p53 tumour suppressor target gene expression by the p52 NF-κB subunit

MDMX regulation of p53 response to ribosomal stress

Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein

Global and gene-specific analyses show distinct roles for Myod and Myog at a common set of promoters

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097